HDL in Sepsis – Risk Factor and Therapeutic Approach

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2015.00244
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

Therapeutic Potential of HDL in Cardioprotection and Tissue Repair

Handbook of Experimental Pharmacology
BiochemistryToxicologyPharmaceuticsPharmacology
2014English

Is Strongyloides Stercoralis a Risk Factor for Sepsis Severity?

Critical Care
Critical CareIntensive Care Medicine
2013English

Therapeutic Interventions in Sepsis: Current and Anticipated Pharmacological Agents

British Journal of Pharmacology
Pharmacology
2014English

Relative Adrenal Insufficiency Is a Risk Factor and an Endotype of Sepsis - A Proof of Concept Study to Support a Precision Medicine Approach for Glucocorticoid Sepsis Therapy

2020English

Statins and Sepsis: Possible Connections and Therapeutic Implications

Biomedical and Pharmacology Journal
Pharmacology
2013English

HSP-Target of Therapeutic Agents in Sepsis Treatment

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Corporate Risk Management: A Multi-Factor Approach

Maandblad Voor Accountancy en Bedrijfseconomie
1995English

The Evolving Experience With Therapeutic TNF Inhibition in Sepsis: Considering the Potential Influence of Risk of Death

Expert Opinion on Investigational Drugs
MedicinePharmacology
2011English

Vancomycin Treatment Is a Risk Factor for Vancomycin-Nonsusceptible Staphylococcus Capitis Sepsis in Preterm Neonates

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy